Arsanis to Present at the Jefferies 2016 Healthcare Conference

WALTHAM, Mass. & VIENNA--()--Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced that its chief executive officer, René Russo, PharmD, BCPS, will present a company overview at the Jefferies 2016 Healthcare Conference in New York City.

The presentation will take place on Tuesday, June 7, 2016, at 11:00 a.m. EDT.

About Arsanis, Inc.

Arsanis is a clinical-stage company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases. The company’s current programs address pathogenic processes selectively, rather than aiming to broadly eliminate bacteria, potentially allowing Arsanis to address critical infections without contributing to the problem of antibiotic resistance. The company is building a broad product pipeline addressing the most important Gram-positive and Gram-negative bacterial pathogens threatening hospitalized and high-risk patients. Its lead therapeutic candidate, ASN100, is aimed at the prevention and treatment of serious Staphylococcus aureus infections and entered a Phase I clinical trial in the fall in 2015, with a Phase II study anticipated to begin in 2016.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

For more information, please visit the Arsanis website at www.arsanis.com.

Contacts

Media:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com
or
Investor Contact:
Michael Gray, 781-819-5201
Chief Financial and Chief Business Officer
mike.gray@arsanis.com

Release Summary

Rene Russo, CEO of Arsanis, will present at the Jefferies 2016 Healthcare Conference on June 7, 2016, at 11:00 a.m. EDT.

Contacts

Media:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com
or
Investor Contact:
Michael Gray, 781-819-5201
Chief Financial and Chief Business Officer
mike.gray@arsanis.com